Suspended

Cipralex&GBMThe Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Escitalopram

+ placebo

Drug
Who is being recruted

Behavior

+ Behavioral Symptoms

+ Depression

From 18 to 80 Years
+18 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Supportive Care Study

Placebo-ControlledPhase 2 & 3
Interventional
Study Start: December 2015
See protocol details

Summary

Principal SponsorTel-Aviv Sourasky Medical Center
Study ContactRachel Grossman, MDMore contacts
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2015

Actual date on which the first participant was enrolled.

This study is planned as prospective randomized, controlled, double-blind study. Patients will undergo resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age,Karnofsky score, extent of tumor resection), for two research groups: Group number 1 will include 50 patients, who will receive Escitalopram or Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months. . The dose study is fixed and is not aimed at symptomatic treatment of anti-depressant (such as major depression).

Official TitleThe Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
NCT02623231
Principal SponsorTel-Aviv Sourasky Medical Center
Study ContactRachel Grossman, MDMore contacts
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Supportive Care Study

These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

BehaviorBehavioral SymptomsDepression

Criteria

5 inclusion criteria required to participate
Aged 18-80
who signed an informed consent form
patients that underwent biopsy or resection of brain glioblastoma.
KPS≥70
Show More Criteria
13 exclusion criteria prevent from participating
Patients who suffered from depression within five years,
Patients treated with antidepressants
Are not able to answer the questionnaires because of an inability to communicate
Patients treated with inhibitors (MAOI) such as: nialamide , isocarboxazid , iproniazid, phenerzine, tranylcypromine
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months

Group II

Placebo
Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

The Tel Aviv Sourasky Medical Center

Tel Aviv, IsraelOpen The Tel Aviv Sourasky Medical Center in Google Maps
SuspendedOne Study Center